The BOOSTER technology exploits the ability of human ferritin engineered compounds to greatly enhance the antitumor activity of virtually any type of co-administered drugs as well as to restore immunological response to cancer. This technology works as booster for both approved drug as well as drugs under clinical development.
For these reasons, Thena Biotech is developing a specific pipeline (named BOOSTER), exploiting the ability of the human ferritin carrier for the selective delivery of multiple BioActive Peptides (BAPs). BAPs are short aminoacid sequences endowed with specific functionalities.
Using a genetic engineering-based approach, Thena’s scientists can functionally graft several BAPs into the ferritin nanovector backbone for their selective delivery in the tumor microenvironment.